Results 181 to 190 of about 236,465 (250)

Awareness of Dental Outreach Camps and Perceptions Toward Mobile Phone-Based Communication Among Dental Outreach Camp Attendees in Chennai: A Cross-Sectional Study. [PDF]

Cureus
Sri K N, Krishnasamy N, Raja B K, Parangimalai Diwakar M, Singaram K, D A.   +5 more
europepmc   +1 more source

Effect of oxycodone vs. morphine as first‐line opioid on new persistent opioid use after orthopaedic surgery: A prospective sequential cohort study

British Journal of Clinical Pharmacology, EarlyView.
Abstract Background Postoperative opioids, intended for short‐term analgesia, contribute to new persistent opioid use in 1%–7% of patients, adversely affecting outcomes. Oxycodone may carry higher risk than morphine, though long‐term data are limited.
Eward J. Melis, Johanna E. Vriezekolk, Frédérique H. C. Bollen, Dirk E. Schrander, Arnt F. A. Schellekens, Bart J. F. van den Bemt   +5 more
wiley   +1 more source

Labelling, Defining and Classifying the Active Ingredients in Oral Language Interventions for Children With or at Risk of Developmental Language Disorder: A Systematic Review and Qualitative Synthesis. [PDF]

Int J Lang Commun Disord
Frizelle P, Murphy D, Murphy L, Fletcher L, O'Leary N, Kerrisk N, Lyons I, Buckley A, Eadie P, Ebbels S, Ferk-Dornstauder M, Jessenitschnig J, Fricke S, Kelic M, Kunnari S, Leitão S, McKean C, McGregor K, Munro N, Murphy CA, Horne AOV.   +20 more
europepmc   +1 more source

Evaluating a virtual paediatric adverse drug reaction clinic

British Journal of Clinical Pharmacology, EarlyView.
Aims Adverse drug reactions (ADRs) are a common problem in paediatric health care. There is limited access to expertise in the evaluation and management of potential ADRs in children, limiting access to these services and creating delays in assessment and management.
Emily Hauck, Blanca Del Pozzo‐Magana, Michael Rieder   +2 more
wiley   +1 more source

Behavioral and Cognitive Strategies in Pediatric Dentistry: Current Concepts in Anxiety and Fear Management. [PDF]

Cureus
Alfadhli HA, Deka Q, Samanta I, Masne SP, Tripathi P, Sriranjan P.   +5 more
europepmc   +1 more source

Pregnancy‐related effect on elexacaftor, tezacaftor and ivacaftor pharmacokinetics in women with cystic fibrosis

British Journal of Clinical Pharmacology, EarlyView.
Aim The number of pregnancies among women with cystic fibrosis (wwCF) has steadily increased over the past decade. However, the pharmacokinetics (PK) of elexacaftor–tezacaftor–ivacaftor (ETI) during gestation remains uncharacterized, despite its widespread use in this population.
Paulette Magnas, Naim Bouazza, Frantz Foissac, Saïk Urien, Léo Froelicher‐Bournaud, Gabrielle Lui, Victoria Guillemart, Nicolas Carlier, Jennifer Da Silva, Johanna Fesenbeckh, Reem Kanaan, Isabelle Honoré, Clémence Martin, Jean‐Marc Treluyer, Vassilis Tsatsaris, Pierre‐Régis Burgel, Sihem Benaboud   +16 more
wiley   +1 more source

Healthcare Providers' Perspectives on Teledentistry Use in Supporting Oral Care of First Nations Children: A Qualitative Study. [PDF]

Int J Paediatr Dent
Arshat N, Arriola-Pacheco F, Cassim N, Mylopoulos M, Wardlaw W, Rodgers G, Lawrence HP.   +6 more
europepmc   +1 more source

UGT1A1 genotype testing for irinotecan: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI‐PGx)

British Journal of Clinical Pharmacology, EarlyView.
Abstract Irinotecan, a topoisomerase I inhibitor, is available as both non‐pegylated and pegylated formulations. The non‐pegylated formulation is licensed for use in advanced colorectal cancer either in combination with other agents or as monotherapy.
Dharmisha Chauhan, Cinzia Dello Russo, Jack Thompson, Dyfrig A. Hughes, Katherine Payne, Maria Tsakiroglou, Paul Ross, Rena Chauhan, Simon Jenkinson, Jessica Keen, Sophie Harding, Eleanor Lau, Michael Braun, Roshan Agarwal, Richard Adams, Elisabeth Rolf, Farah Al‐Sheikhli, Sarah Mitchell, Ruth Hammond, Rosie Roberts, Lorna Cairns, Shirley Heggarty, Janet Graham, Justin Mencel, Munir Pirmohamed   +24 more
wiley   +1 more source

Impact of the pancreatic enzyme replacement therapy (PERT) shortage on prescribing in England: Analysis of national data

British Journal of Clinical Pharmacology, EarlyView.
Aim Pancreatic enzyme replacement therapy (PERT) is essential for the management of pancreatic exocrine insufficiency. Since June 2023, the United Kingdom has been affected by a global shortage of PERT. We investigated the impact of this shortage on national prescribing trends for Creon, Nutrizym, Pancrex and Pangrol.
Teena S. Varghese, Mary E. Phillips, Louis Fisher, Helen Fitt, Adam Frampton, Christopher Wood, Agnieszka Lemanska   +6 more
wiley   +1 more source